UK Peptide Regulation Hub
A reader's guide to how UK regulation actually applies to peptide research, unapproved compounds, prescription-only medicines, and the lines that turn a 'research chemical' into a medicinal product. Educational only — not legal advice.
UK peptide law & the MHRA
High-level explanation of the medicinal-product concept and why claims and intended use matter more than labels.
Unlicensed medicines & 'specials'
What 'specials' are, why they exist, and why this is a clinician-led route — not a self-purchase route.
POM advertising rules
Why prescription-only medicines (including GLP-1 agonists) cannot be advertised to the public, and why we avoid promotional framing.
Research chemicals vs medicines
Intended use, claims, and the supply context determine whether a compound is regulated as a medicine — labels do not.
Borderline products
When does a peptide cross the line into being a medicinal product, and why is this ambiguous in practice?
Anti-doping & WADA
Why peptides are heavily scrutinised in elite sport. Athletes should seek qualified anti-doping advice — we do not.
Importation risks
Customs and regulatory uncertainty around peptide importation into the UK. We do not provide sourcing guidance.
Pages on PeptideStacks are reviewed when relevant new evidence becomes available. If you spot an error or have new evidence to suggest, please use our corrections policy.